Simultaneous HPTLC Determination Of Gliclazide And Rosiglitazone In Tablets
An HPTLC method has been developed for the simultaneous estimation of gliclazide and rosiglitazone from its combined dosage form. The method involves separation of components by TLC on a precoated silica gel 60 F 254 plate using a mixture of toluene:ethylacetate:methanol (85:5:10) as the mobile phase. Detection of the spot was carried out at 225 nm in absorbance mode. The retardation factors of gliclazide and rosiglitazone were found to be 0.36 and 0.47, respectively. The linearity range was found to be 1-3 Î¼g/10 Î¼I for gliclazide and 0.05-0.1 5 Î¼g/10 Î¼1 for rosiglitazone.